232 related articles for article (PubMed ID: 29564668)
1. Acute Liver Failure from Tumor Necrosis Factor-α Antagonists: Report of Four Cases and Literature Review.
Kok B; Lester ELW; Lee WM; Hanje AJ; Stravitz RT; Girgis S; Patel V; Peck JR; Esber C; Karvellas CJ;
Dig Dis Sci; 2018 Jun; 63(6):1654-1666. PubMed ID: 29564668
[TBL] [Abstract][Full Text] [Related]
2. A case report: ulcerative colitis, treatment with an antibody against tumor necrosis factor (infliximab), and subsequent liver necrosis.
Kinnunen U; Färkkilä M; Mäkisalo H
J Crohns Colitis; 2012 Jul; 6(6):724-7. PubMed ID: 22398069
[TBL] [Abstract][Full Text] [Related]
3. Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases.
Ghabril M; Bonkovsky HL; Kum C; Davern T; Hayashi PH; Kleiner DE; Serrano J; Rochon J; Fontana RJ; Bonacini M;
Clin Gastroenterol Hepatol; 2013 May; 11(5):558-564.e3. PubMed ID: 23333219
[TBL] [Abstract][Full Text] [Related]
4. [A 20-year-old woman with ulcerative colitis and acute liver failure].
Forker R; Escher M; Stange EF
Internist (Berl); 2017 Sep; 58(9):982-989. PubMed ID: 28271269
[TBL] [Abstract][Full Text] [Related]
5. New Onset Autoimmune Hepatitis during Anti-Tumor Necrosis Factor-Alpha Treatment in Children.
Ricciuto A; Kamath BM; Walters TD; Frost K; Carman N; Church PC; Ling SC; Griffiths AM
J Pediatr; 2018 Mar; 194():128-135.e1. PubMed ID: 29274889
[TBL] [Abstract][Full Text] [Related]
6. Infliximab-associated fulminant hepatic failure in ulcerative colitis: a case report.
Parra RS; Feitosa MR; Machado VF; Ramalho LN; da Rocha JJ; Feres O
J Med Case Rep; 2015 Oct; 9():249. PubMed ID: 26518665
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumour necrosis factor agent and liver injury: literature review, recommendations for management.
Rossi RE; Parisi I; Despott EJ; Burroughs AK; O'Beirne J; Conte D; Hamilton MI; Murray CD
World J Gastroenterol; 2014 Dec; 20(46):17352-9. PubMed ID: 25516646
[TBL] [Abstract][Full Text] [Related]
8. Risk of drug-induced liver injury from tumor necrosis factor antagonists.
Björnsson ES; Gunnarsson BI; Gröndal G; Jonasson JG; Einarsdottir R; Ludviksson BR; Gudbjörnsson B; Olafsson S
Clin Gastroenterol Hepatol; 2015 Mar; 13(3):602-8. PubMed ID: 25131534
[TBL] [Abstract][Full Text] [Related]
9. Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis.
Baki E; Zwickel P; Zawierucha A; Ehehalt R; Gotthardt D; Stremmel W; Gauss A
World J Gastroenterol; 2015 Mar; 21(11):3282-90. PubMed ID: 25805935
[TBL] [Abstract][Full Text] [Related]
10. Nephrotic syndrome after infliximab treatment in a patient with ulcerative colitis.
Dumitrescu G; Dahan K; Treton X; Corcos O; Bouhnik Y; Stefanescu C
J Gastrointestin Liver Dis; 2015 Jun; 24(2):249-51. PubMed ID: 26114187
[TBL] [Abstract][Full Text] [Related]
11. Paradoxical articular manifestations in patients with inflammatory bowel diseases treated with infliximab.
Thiebault H; Boyard-Lasselin P; Guignant C; Guillaume N; Wacrenier A; Sabbagh C; Rebibo L; Brazier F; Meynier J; Nguyen-Khac E; Dupas JL; Goëb V; Fumery M
Eur J Gastroenterol Hepatol; 2016 Aug; 28(8):876-81. PubMed ID: 27101404
[TBL] [Abstract][Full Text] [Related]
12. Incidence and Management of Infusion Reactions to Infliximab in an Alternate Care Setting.
Checkley LA; Kristofek L; Kile S; Bolgar W
Dig Dis Sci; 2019 Mar; 64(3):855-862. PubMed ID: 30311152
[TBL] [Abstract][Full Text] [Related]
13. Significant risk and associated factors of active tuberculosis infection in Korean patients with inflammatory bowel disease using anti-TNF agents.
Kim ES; Song GA; Cho KB; Park KS; Kim KO; Jang BI; Kim EY; Jeon SW; Lee HS; Yang CH; Lee YK; Lee DW; Kim SK; Kim TO; Lee J; Kim HW; Jee SR; Park SJ; Kim HJ
World J Gastroenterol; 2015 Mar; 21(11):3308-16. PubMed ID: 25805938
[TBL] [Abstract][Full Text] [Related]
14. Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents.
Eickstaedt JB; Killpack L; Tung J; Davis D; Hand JL; Tollefson MM
Pediatr Dermatol; 2017 May; 34(3):253-260. PubMed ID: 28211161
[TBL] [Abstract][Full Text] [Related]
15. Psoriasiform Skin Lesions Are Caused by Anti-TNF Agents Used for the Treatment of Inflammatory Bowel Disease.
George LA; Gadani A; Cross RK; Jambaulikar G; Ghazi LJ
Dig Dis Sci; 2015 Nov; 60(11):3424-30. PubMed ID: 26115749
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor necrosis factor (TNF)-induced lupus in a patient with hidradenitis suppurativa.
Turk D; Vellaichamy G; Lyons AB; Parks-Miller A; Nelson T; Meysami A; Hamzavi IH
Int J Dermatol; 2020 Mar; 59(3):e73-e74. PubMed ID: 31633193
[No Abstract] [Full Text] [Related]
17. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy.
Lozeron P; Denier C; Lacroix C; Adams D
Arch Neurol; 2009 Apr; 66(4):490-7. PubMed ID: 19364934
[TBL] [Abstract][Full Text] [Related]
18. Fibrosing cholestatic hepatitis after methotrexate and prednisone therapy for rheumatoid arthritis.
Topaloğlu S; Çalık A; Kalaycı O; Çeşmecioğlu E; Çobanoğlu Ü; Uzun Y
Exp Clin Transplant; 2014 Mar; 12 Suppl 1():95-7. PubMed ID: 24635802
[TBL] [Abstract][Full Text] [Related]
19. Repeated intensified infliximab induction - results from an 11-year prospective study of ulcerative colitis using a novel treatment algorithm.
Johnsen KM; Goll R; Hansen V; Olsen T; Rismo R; Heitmann R; Gundersen MD; Kvamme JM; Paulssen EJ; Kileng H; Johnsen K; Florholmen J
Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):98-104. PubMed ID: 27749779
[TBL] [Abstract][Full Text] [Related]
20. Compassionate access anti-tumour necrosis factor-α therapy for ulcerative colitis in Australia: the benefits to patients.
Costello SP; Ghaly S; Beswick L; Pudipeddi A; Agarwal A; Sechi A; O'Connor S; Connor SJ; Sparrow MP; Bampton P; Walsh AJ; Andrews JM;
Intern Med J; 2015 Jun; 45(6):659-66. PubMed ID: 25732268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]